| Study Name |
Design/ Requirements |
Eligibility Criteria |
Statin Study: Evaluates the safety and efficacy of simvastatin to slow the progression of AD.
Closed: Not recruiting
|
- 18 months.
- Labs.
- Psychological tests.
- 6-7 clinical visits.
- Simvastatin.
|
- Age 50 or older.
- Mild to moderate AD .
- Not taking a statin.
- No known heart disease.
- Closed: Not recruiting
|
Homocysteine Study: Reducing homocysteine to slow cognitive decline in AD
Closed: Not recruiting
|
- 18 months
- Labs
- Psychological tests.
- 7-8 clinic visits
- MRI
- ECG
- Vitamin B
|
- Age 55 or older
- The first trial is open to persons with and without AD – couples are ideal
- Closed: Not recruiting
|
DHA
Can Omeg-3 fatty acids (DHA) slow the progression of Alzheimer's Disease. |
- 18 Months
- Regular Clinic visits
- Neuropsychological tests
|
- Age >50.
- Mild to moderate Alzheimer's Disease
- Fluent in English or Spanish
- A friend or relative who can accompany the vounteer to all clinic visits
|
ADNI
How brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD).
Closed: Not recruiting
|
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Lumbar Puncture (LP)
|
- Age 50-90.
- MCI
- A study partner.
- Able to undergo neuroimaging.
- Closed: Not recruiting
|
APOE Study: The effect of APOE genotype on CSF cortisol concentrations in person with AD, nondemented older persons, and normal young and middle-aged persons will be determined
Closed: Not recruiting
|
- Spinal fluid cortisol levels obtained through lumbar puncture
- Very brief study ~ 2 weeks`
|
- Age 18-90
- Non smoking for 6 months
- AD and cognitively normal patients
- Closed: Not recruiting
|
Huperzine A: assess the tolerability and effectiveness of Huperzine A in improving cognitive function in AD
Closed: Not recruiting
|
- 24 weeks
- Clinic visits
- Psychological tests
- Labs
|
- Persons with AD.
- Not taking cholinesterase inhibitors
- Closed: Not recruiting
|
| Elan AAB-001 The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD) Closed Not recruiting |
|
- Diagnosis of probable AD
- Age from 50 to 85 years
- Magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD
- Fluency in English
- Stable doses of medications
- Closed Not recruiting
|
Cognitive assessment
Physical assessment of cranial nerves, vision, hearing, and speech
Tests for coordination and motor function
Evaluation of movement disorders, reflexes, posture and gait